Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
Condition: Leukemia, Acute Myeloid; Myelodysplastic Syndrome
MeSH terms: Leukemia; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Syndrome
Intervention: temozolomide
Intervention MeSH terms: Temozolomide
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 47.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The primary objective of this study is to evaluate the safety, tolerability, and efficacy of
      temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants
      who are not candidates for standard induction therapy and exhibit low MGMT expression.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of acute myeloid leukemia (AML), any subtype except acute
             promyelocytic leukemia (APL), by the World Health Organization (WHO) criteria, or high
             risk MDS with blasts between 10 and 20% in the bone marrow.

          -  No prior AML chemotherapy except hydroxyurea.

          -  Leukemic blast count <30x10^9/L at the start of therapy. Prior cytoreduction with
             hydroxyurea (maximum 14 days) is permitted.

          -  Participant is not a candidate for aggressive induction based on at least one of the
             following: adverse-risk cytogenetics (complete or partial deletion of 5 or 7, complex
             [>3] cytogenetic abnormalities, inv3, 11q23 abnormalities); secondary AML (antecedent
             hematologic disorder or therapy-related AML); comorbid medical illnesses precluding
             standard induction therapy; participant's refusal of standard induction therapy.

          -  Confirmed low MGMT expression (MGMT: beta-actin ≤0.2), as evaluated by Western blot,
             or weak MGMT expression defined as > 0.2 and ≤2.5 if promoter is methylated, upon
             Sponsor approval.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Use of medically approved contraception in fertile males and females.

          -  Negative urine or serum pregnancy test for women of childbearing potential (72 hours
             prior to Baseline).

        Exclusion Criteria:

          -  Serum bilirubin >2 times the upper limit of normal (ULN), or serum aspartate
             aminotransferase/ alanine aminotransferase >5 times ULN.

          -  Serum creatinine >200 umol/L.

          -  History of other malignancies within 1 year prior to study entry, with the exception
             of localized nonmelanomatous skin cancer or cervical cancer in situ.

          -  Presence of active uncontrolled infection.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Any medical condition that may interfere with protocol evaluation or oral medication
             intake.

          -  Prior chemotherapy other than hydroxyurea.